Details of Disease

General Information of Disease (ID: DISMYBW9)

• Disease Name: Dysmenorrhea
• Disease Class: GA34: Female pelvic pain
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISMYBW9: Dysmenorrhea
• ICD Code:
  ICD-11: ICD-11: GA34.3
  ICD-9: ICD-9: 625.3
  Expand ICD-11: 'GA34.3
  Expand ICD-10: 'N94.4; 'N94.5; 'N94.6
  Expand ICD-9: 625.3
• Disease Identifiers:
  MESH ID: D004412
  MedGen ID: 4429
  HPO ID: HP:0100607
  SNOMED CT ID: 266599000

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 16 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Butylscopolamine	DMZKXB7	Approved	Small molecular drug	[1]
Caffeine	DMKBJWP	Approved	Small molecular drug	[2]
Celecoxib	DM6LOQU	Approved	Small molecular drug	[3]
Clonixin	DMVO3JM	Approved	Small molecular drug	[1]
Dexibuprofen	DMFYBD0	Approved	Small molecular drug	[4]
Diclofenac	DMPIHLS	Approved	Small molecular drug	[5]
Fentiazac	DMCQ7UN	Approved	Small molecular drug	[1]
Flufenamic Acid	DMC8VNH	Approved	Small molecular drug	[6]
Ibuprofen	DM8VCBE	Approved	Small molecular drug	[7]
Ketoprofen	DMRKXPT	Approved	Small molecular drug	[8]
Lidocaine	DML4ZOT	Approved	Small molecular drug	[9]
Meclofenamic acid	DM05FXR	Approved	Small molecular drug	[10]
Mefenamic acid	DMK7HFI	Approved	Small molecular drug	[11]
Mepyramine	DMB4SFH	Approved	Small molecular drug	[12]
Naproxen	DMZ5RGV	Approved	Small molecular drug	[13]
Pirprofen	DMMOFHT	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NPC-01	DMMC3Y8	Phase 3	NA	[14]
Lithium	DMZ3OU6	Phase 2	Small molecular drug	[15]
VA-111913	DMAYWXD	Phase 2	Small molecular drug	[16]
PDC-41	DM74YO8	Phase 1	NA	[17]
SRX-251	DMO1N8A	Phase 1	NA	[18]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PSD-508	DMR1OJM	Discontinued in Phase 2	NA	[19]
JTV-605	DM89TXB	Terminated	Small molecular drug	[20]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
K-133W	DM9VZOL	Investigative	NA	[21]
PDC-31	DMUDY7H	Investigative	NA	[22]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Caffeine FDA Label
• [3] Celecoxib FDA Label
• [4] ADIDAC trial: analgesia with dexibuprofen versus ibuprofen in patients suffering from primary dysmenorrhea: a crossover trial. Gynecol Obstet Invest. 2009;67(1):25-31.
• [5] Diclofenac FDA Label
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2447).
• [7] Ibuprofen FDA Label
• [8] Ketoprofen FDA Label
• [9] ClinicalTrials.gov (NCT00651313) Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods). U.S. National Institutes of Health.
• [10] Use of meclofenamic acid in gynecology and obstetrics: effects on postsurgical stress. Clin J Pain. 1991;7 Suppl 1:S60-3.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2593).
• [12] Naproxen, paracetamol and pamabrom versus paracetamol, pyrilamine and pamabrom in primary dysmenorrhea: a randomized, double-blind clinical trial. Medwave. 2016 Oct 24;16(9):e6587.
• [13] Naproxen FDA Label
• [14] ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health.
• [15] Lithium FDA Label
• [16] ClinicalTrials.gov (NCT00963053) VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT01250587) Dose-Finding Study of PDC31 in Patients With Primary Dysmenorrhea. U.S. National Institutes of Health.
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025117)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027456)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010443)
• [21] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 344).